Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Bone sarcoma statistics
New cases of bone sarcoma, 2015, UK
Deaths from bone sarcoma, 2016, UK.
Survive bone sarcoma for 10 or more years, 2009-2013, England
- There were around 580 new cases of bone sarcoma in the UK in 2014, that’s around 2 cases diagnosed every day.
- Bone sarcoma accounts for less than 1% of all new cases in the UK (2014).
- In males, there were around 310 cases of bone sarcoma diagnosed in the UK in 2014.
- In females, there were around 270 cases of bone sarcoma diagnosed in the UK in 2014.
- More than half (53%) of bone cancer cases in the UK each year are diagnosed in people aged 45 and over (2012-2014).
- Incidence rates for bone sarcoma in the UK are highest in people aged 85+ (2012-2014).
- Since the early 1990s, bone sarcoma incidence rates have increased by more than a tenth (14%) in the UK. This includes stable rates in males and an increase in females.
- Over the last decade, bone sarcoma incidence rates have remained stable in the UK, for males and females separately and for both sexes combined.
- Most bone sarcomas occur in the lower limbs.
- Incidence rates for bone sarcoma are projected to fall by 5% in the UK between 2014 and 2035, to 1 case per 100,000 people by 2035.
- 1 in 1,140 men and 1 in 1,660 women will be diagnosed with bone sarcoma during their lifetime.
- Bone sarcoma in England is not associated with deprivation.
- An estimated 69,100 people who had previously been diagnosed with bladder cancer were alive in the UK at the end of 2010.
- There are around 350 bone sarcoma deaths in the UK every year, that's around 1 every day (2014-2016).
- Bone sarcoma is not among the 20 most common causes of cancer death in the UK, accounting for less than 1% of all cancer deaths (2016).
- In males in the UK, bone sarcoma is the 20th most common cause of cancer death, with around 220 deaths in 2016.
- In females in the UK, bone sarcoma is not among the 20 most common causes of cancer death, with around 140 deaths in 2016.
- Mortality rates for bone sarcoma in the UK are highest in people aged 90+ (2014-2016).
- Since the early 1970s, bone sarcoma mortality rates have decreased by almost three-fifths (55%) in the UK. Rates in males have decreased by almost three-fifths (58%), and rates in females have decreased by almost three-fifths (55%).
- Over the last decade, bone sarcoma mortality rates have remained stable in the UK. Rates in males have remained stable, and rates in females have remained stable.
- Mortality rates for bone sarcoma are projected to fall by 23% in the UK between 2014 and 2035, to 1 death per 100,000 people by 2035.
- Bone sarcoma in England is not associated with deprivation.
- More than half (55%) of people diagnosed with bone sarcoma in England survive their disease for ten years or more (2009-2013).
- More than 6 in 10 (62%) people diagnosed with bone sarcoma in England survive their disease for five years or more (2009-2013).
- More than 8 in 10 (83%) people diagnosed with bone sarcoma in England survive their disease for one year or more (2009-2013).
- Bone sarcoma 10-year survival in England is similar in men and women (2009-2013).
- Bone sarcoma five-year survival in England in males is highest for those diagnosed at 50-59 years old and in females is highest for those diagnosed at 15-49 years old (2009-2013).
- More than 7 in 10 people in England diagnosed with bone sarcoma aged 50-59 survive their disease for five years or more, compared with around 4 in 10 people diagnosed aged 70-89 (2009-2013).
- Five-year relative survival for bone sarcoma in men is similar to the European average in England and Northern Ireland but below the European average in Scotland
- Five-year relative survival for bone sarcoma in women is similar to the European average in England, Wales and Northern Ireland but below the European average in Scotland.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ is met by all but Northern Ireland and Wales, and ’62 day wait’ is not met by any country for sarcoma.
- 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- Around 8 in 10 patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for bone sarcoma in the UK are; incidence 2015, mortality 2016, and survival 2009-2013.
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2010-2012 due to the small number of cases.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Overall, the evidence on bone sarcoma risk factors is limited, mainly because of the relative rarity and diversity of this group of cancers. Studies which group together different morphological subtypes of bone sarcoma may be confounded if those subtypes have differing aetiologies. Where available, evidence from studies which define bone sarcomas by tumour morphology are cited; if studies define by ICD-9 or ICD-10 anatomical site only this is noted.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Bone sarcoma is part of the group 'Sarcoma' for cancer waiting times data. Codes vary per country but broadly include: bone and articular cartilage, Kaposi sarcoma, retroperitoneum and peritoneum, other connective and soft tissue, secondary cancers of retroperitoneum and peritoneum, secondary cancers of bone and bone marrow.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.
When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or
We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.